Laura Ley

ORCID: 0009-0003-9881-4693
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Psychedelics and Drug Studies
  • Neurotransmitter Receptor Influence on Behavior
  • Chemical synthesis and alkaloids
  • Forensic Toxicology and Drug Analysis
  • Biochemical Analysis and Sensing Techniques
  • Cannabis and Cannabinoid Research
  • Antibiotics Pharmacokinetics and Efficacy
  • Functional Brain Connectivity Studies
  • Electroconvulsive Therapy Studies
  • Religious Studies and Spiritual Practices
  • Chromatography in Natural Products
  • Paranormal Experiences and Beliefs
  • Mental Health and Psychiatry
  • Heart Rate Variability and Autonomic Control
  • Chemical Reactions and Isotopes
  • Advanced Chemical Sensor Technologies
  • Motivation and Self-Concept in Sports
  • Olfactory and Sensory Function Studies
  • Dermatology and Skin Diseases
  • Complementary and Alternative Medicine Studies
  • Alkaloids: synthesis and pharmacology
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Pharmacological Effects of Natural Compounds
  • Muscle activation and electromyography studies
  • Plant and fungal interactions

University of Basel
2019-2025

University Hospital of Basel
2019-2025

Pontifícia Universidade Católica do Rio Grande do Sul
2023

Abstract Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) an empathogen, and d -amphetamine stimulant. All three substances are used recreationally. LSD MDMA being investigated as medications to assist psychotherapy, for the treatment of attention-deficit/hyperactivity disorder. induce distinct acute subjective effects. However, differences in responses these prototypical psychoactive have not been characterized controlled study. We...

10.1038/s41386-019-0569-3 article EN cc-by Neuropsychopharmacology 2019-11-16

Growing interest has been seen in using lysergic acid diethylamide (LSD) psychiatric research and therapy. However, no modern studies have evaluated subjective autonomic effects of different pharmaceutically well-defined doses LSD. We used a double-blind, randomized, placebo-controlled, crossover design 16 healthy subjects (eight women, eight men) who underwent six 25 h sessions received placebo, LSD (25, 50, 100, 200 µg), µg 1 after administration the serotonin 5-hydroxytryptamine-2A...

10.1038/s41386-020-00883-6 article EN cc-by Neuropsychopharmacology 2020-10-15

Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin psychiatric research therapy. However, no modern studies have evaluated differences subjective autonomic effects of LSD or their similarities dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design 28 healthy subjects (14 women, 14 men) who underwent five 25 h sessions received placebo, (100 200 µg), (15 30 mg). Test days were separated by at least 10 days....

10.1038/s41386-022-01297-2 article EN cc-by Neuropsychopharmacology 2022-02-25

Abstract Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects these substances is lacking. The main goal present study was to investigate potential pharmacological, physiological phenomenological differences at psychoactive-equivalent doses mescaline, LSD, psilocybin. used a randomized, double-blind, placebo-controlled, cross-over design compare acute subjective effects, autonomic pharmacokinetics...

10.1038/s41386-023-01607-2 article EN cc-by Neuropsychopharmacology 2023-05-25

N,N-dimethyltryptamine (DMT) is distinct among classic serotonergic psychedelics because of its short-lasting effects when administered intravenously. Despite growing interest in the experimental and therapeutic use intravenous DMT, data are lacking on clinical pharmacology. We conducted a double-blind, randomized, placebo-controlled crossover trial 27 healthy participants to test different DMT administration regimens: placebo, low infusion (0.6 mg/min), high (1 bolus + (15 mg 0.6 (25 1...

10.1038/s41398-023-02477-4 article EN cc-by Translational Psychiatry 2023-05-23

LSD and psilocybin are increasingly used in phase I trials evaluated as therapeutic agents for mental disorders. The phenomenon of reoccurring drug-like experiences after the acute substance effects have worn off was described both substances especially attributed to LSD. According DSM-V, persisting distressing manifestation these is called hallucinogen-persisting perception disorder (HPPD). Data on conditions very limited.This study aims provide descriptive data administration controlled...

10.1007/s00213-022-06066-z article EN cc-by Psychopharmacology 2022-01-25

Abstract Psychedelics have emerged as promising candidate treatments for various psychiatric conditions, and given their clinical potential, there is a need to identify biomarkers that underlie effects. Here, we investigate the neural mechanisms of lysergic acid diethylamide (LSD) using regression dynamic causal modelling (rDCM), novel technique assesses whole-brain effective connectivity (EC) during resting-state functional magnetic resonance imaging (fMRI). We modelled data from two...

10.1038/s41386-023-01574-8 article EN cc-by Neuropsychopharmacology 2023-04-25

There is renewed interest in the use of lysergic acid diethylamide (LSD) psychiatric research and practice. Although acute subjective effects LSD are mostly positive, negative effects, including anxiety, may occur. The induction overall positive desired psychedelic-assisted therapy because experiences associated with greater therapeutic long-term benefits. 3,4-Methylenedioxymethamphetamine (MDMA) produces marked used recreationally LSD, known as "candyflipping." present study investigated...

10.1038/s41386-023-01609-0 article EN cc-by Neuropsychopharmacology 2023-05-31

Patients with psychotic disorders present alterations in thalamocortical intrinsic functional connectivity as measured by resting-state magnetic resonance imaging. Specifically, thalamic is increased sensorimotor cortices (hyperconnectivity) and decreased prefrontal limbic (hypoconnectivity). Psychedelics such lysergic acid diethlyamide (LSD) elicit similar hyperconnectivity areas healthy volunteers. It unclear whether LSD also induces hypoconnectivity cortices, because current findings are...

10.1016/j.bpsc.2022.04.003 article EN cc-by-nc-nd Biological Psychiatry Cognitive Neuroscience and Neuroimaging 2022-04-29

Psilocybin is being studied for its therapeutic potential in various mental health disorders, such as depression, anxiety, and addiction. Initial studies suggested that psilocybin generally safe when used under controlled conditions, but more research needed to better understand safety profile. We report pharmacology data from a pooled analysis of three randomized crossover included 85 healthy participants 113 single-dose administrations psilocybin. Single oral doses 15 mg, 20 25 30 mg...

10.1016/j.nsa.2024.104060 article EN cc-by-nc-nd Neuroscience Applied 2024-01-01

Background: 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) is used both recreationally and therapeutically. Little known about the factors influencing inter- intra-individual differences in acute response to MDMA. Effects of other psychoactive substances have been shown be critically influenced by personality traits mood state before intake. Methods: We pooled data from 10 randomized, double-blind, placebo-controlled, cross-over studies performed same laboratory 194 healthy subjects...

10.1177/0269881121998322 article EN cc-by-nc Journal of Psychopharmacology 2021-03-30

Abstract It has been reported that serotonergic hallucinogens like lysergic acid diethylamide (LSD) induce decreases in functional connectivity within various resting-state networks. These alterations were seen as reflecting specific neuronal effects of and it was speculated these shifts underlie the characteristic subjective drug effects. In this study, we test hypothesis are not for but they can be induced by monoaminergic stimulation using non-hallucinogenic...

10.1038/s41386-020-00906-2 article EN cc-by Neuropsychopharmacology 2020-11-20

The indole alkaloid N,N-dimethyltryptamine (DMT) induces psychedelic effects in humans. In addition to ceremonial and recreational use, DMT is subject clinical investigations. Sensitive bioanalytical methods are required assess the pharmacokinetics of its metabolites human plasma. Here, a high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification major indole-3-acetic acid (IAA) DMT-N-oxide (DMT-NO) was developed validated. As IAA an endogenous...

10.1016/j.jchromb.2022.123534 article EN cc-by Journal of Chromatography B 2022-11-11

Mescaline is a psychedelic phenethylamine found in different species of cacti. Currently, mescaline's acute subjective effects and pharmacokinetics are investigated several modern clinical studies. Therefore, we developed bioanalytical method for the rapid quantification mescaline its metabolites human plasma. 3,4,5-trimethoxyphenylacetic acid (TMPAA), N-acetyl (NAM), 3,5-dimethoxy-4-hydroxyphenethylamine (4-desmethyl mescaline) were simultaneously analyzed by ultra-high performance liquid...

10.1016/j.jpba.2022.114980 article EN cc-by Journal of Pharmaceutical and Biomedical Analysis 2022-08-02

While the exploration of serotonergic psychedelics as psychiatric medicines deepens, so does pressure to better understand how these compounds act on brain. We used a double-blind, placebo-controlled, crossover design and administered lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), d-amphetamine in 25 healthy participants. By employing spectral dynamic causal modeling, we mapped substance-induced changes effective-connectivity between thalamus different cortex...

10.1016/j.bpsc.2023.07.010 article EN cc-by-nc-nd Biological Psychiatry Cognitive Neuroscience and Neuroimaging 2023-07-31

Background: Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Questionnaire (MEQ)). The psychometric potential of non-MEQ items PES remains largely unexplored. Aims: We investigated whether also yields subscales besides MEQ30 subscales. Methods: Data from 239 measurements (140 healthy participants) six studies moderate high doses lysergic acid diethylamide and/or psilocybin were included. New (with other than...

10.1177/02698811231199112 article EN cc-by-nc Journal of Psychopharmacology 2023-10-31

Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total 48 participants 96 mescaline administrations. Single oral‐dose administrations ( n = 16/dose) at doses 100–800 mg were used. Acute subjective autonomic effects acute subacute adverse recorded. Liver kidney function, blood cell...

10.1111/bcp.16349 article EN cc-by-nc British Journal of Clinical Pharmacology 2024-11-25

This study aimed to develop the Brazilian instrument for assessing eating disorders in children and adolescents test its psychometric quality using item response theory (IRT).Cross-sectional study.Participants aged between five twelve years old of both sexes.IRT logistic model two parameters was used evaluate item's severity discrimination information curve symptoms disorders' latent trait symptoms. Content validity reliability were also assessed. The IRT evaluation suggested that contained...

10.1016/j.aprim.2023.102599 article EN cc-by-nc-nd Atención Primaria 2023-03-09
Coming Soon ...